Can a GLP-1 treat fatty liver disease (MASH)?

For years, fatty liver disease had no approved drug — the only advice was to lose weight. That changed twice in eighteen months, and the second change involved a GLP-1. This page explains what a GLP-1 can and cannot do for the liver, what the trial actually measured, and why the word “accelerated” in “accelerated approval” matters. It contains no dosing instructions and describes evidence only — it does not tell anyone with a fatty liver to seek or self-prescribe a GLP-1. A MASH diagnosis and its treatment belong with a qualified clinician, usually a hepatologist.

What fatty liver disease is — and the 2023 name change

Your liver is not meant to store much fat. When it does, in someone with metabolic risk factors (excess weight, type 2 diabetes, high blood pressure, abnormal cholesterol), doctors now call it MASLD — metabolic dysfunction-associated steatotic liver disease. Most people with MASLD feel fine and never get sick from it.

In a subset, the fat comes with inflammation and liver-cell injury. That more dangerous form is MASH — metabolic dysfunction-associated steatohepatitis — and it is what can slowly scar the liver. Scarring is staged from F0 (none) to F4 (cirrhosis); as it advances toward cirrhosis, the risk of liver failure, liver cancer, and death climbs. That is why drug treatment targets MASH — not simple fatty liver — and specifically people with moderate-to-advanced fibrosis (F2–F3) who have not yet reached cirrhosis.

If you learned the older terms: in 2023 an international expert panel retired them because “nonalcoholic” was seen as vague and stigmatizing. NAFLD became MASLD, and NASH became MASH. The disease is the same; the name changed.

The key trial: ESSENCE

Semaglutide’s liver approval rests on ESSENCE, a phase-3 randomized, double-blind, placebo-controlled trial in adults with biopsy-confirmed MASH and F2–F3 fibrosis, published in the New England Journal of Medicine in 2025. At a prespecified 72-week analysis, both primary endpoints were met, and the effect sizes are large for this field:

• Steatohepatitis resolved without worse scarring in 62.9% on semaglutide versus 34.3% on placebo — a difference of about 29 percentage points.
• Liver scarring (fibrosis) improved without worsening the steatohepatitis in 36.8% versus 22.4% — a difference of about 14 percentage points.

The semaglutide group also lost about 10.5% of body weight (versus 2.0% on placebo), and the side effects were the familiar GLP-1 gastrointestinal ones. On the strength of these biopsy results, this is solid, well-controlled human evidence.

Why “accelerated approval” is the whole story

On August 15, 2025, the FDA gave accelerated approval to Wegovy (semaglutide 2.4 mg) for noncirrhotic MASH with moderate-to-advanced fibrosis — making it the first GLP-1, and only the second drug of any kind, approved for MASH. (The first, in 2024, was resmetirom/Rezdiffra, a non-GLP-1 that acts directly on liver metabolism.)

Here is the caveat baked into that same approval. MASH resolution and one-stage fibrosis improvement are surrogate endpoints — they describe what the liver looks like at 72 weeks, not whether people avoided cirrhosis, liver failure, transplant, or death years later. The label says so directly: the indication is “approved under accelerated approval based on improvement of MASH and fibrosis,” and continued approval “may be contingent upon the verification and description of clinical benefit in a confirmatory trial.” That confirmatory trial (ESSENCE Part 2) is designed to answer the outcomes question, with results expected around 2029. So the honest framing is: strong proof the drug improves liver histology, and reasonable expectation — not yet proof — that this translates into fewer bad outcomes. The approval also does not cover cirrhosis (F4); those patients were not studied.

Is the liver benefit beyond weight loss?

This is the question a skeptical reader should ask, and the honest answer is layered. Weight loss alone genuinely improves MASLD/MASH — losing roughly 10% of body weight can resolve steatohepatitis and even reverse some scarring, which is why weight loss is the guideline-recommended first step. In ESSENCE, the semaglutide group lost right about that much, so a large part of the benefit is almost certainly the weight loss the drug produces.

Is there anything extra? A secondary analysis of ESSENCE suggested semaglutide improved liver measures more than placebo even at similar weight loss, hinting at a weight-independent liver effect. That is mechanistically plausible, but it is a secondary, conference-stage analysis prone to confounding — preliminary, not settled. The most defensible statement today: most of the benefit tracks with weight loss, with suggestive-but-not-conclusive evidence of an additional direct liver effect.

What about tirzepatide and the other GLP-1s?

The most important dataset is SYNERGY-NASH, a phase-2 trial of tirzepatide (the dual GIP/GLP-1 agonist) in NEJM in 2024. In 190 adults with F2–F3 MASH, MASH resolved without worsening fibrosis in roughly 44–62% across doses versus about 10% on placebo — encouraging numbers. But this is a phase-2, dose-finding trial of 190 people, and tirzepatide is not FDA-approved for MASH. A class effect is reasonable to expect given how these drugs work, but “expected” is not “proven.” Grade for tirzepatide-for-MASH: promising but unproven.

What we still don’t know

• Whether improving 72-week biopsy findings actually reduces cirrhosis, liver failure, transplant, and death — the outcomes that matter (answered by ESSENCE Part 2, around 2029).
• Whether the benefit persists, and what happens to the liver if the drug is stopped and weight is regained.
• Whether GLP-1s help people who already have cirrhosis (F4) — they were excluded from these trials, so a benefit there should not be assumed safe or effective.
• How GLP-1s compare with, or combine with, resmetirom.

One thing that is not uncertain: alcohol is central to liver outcomes. Whatever the drug does, cutting back on alcohol is part of caring for a fatty liver, and it is worth raising directly with your hepatologist (see the alcohol page).

“A weekly shot cures fatty liver” overstates it: it cures nothing, is approved only for the inflammatory/scarring form (not simple fatty liver and not cirrhosis), and the proof so far is a biopsy at 72 weeks. But “it’s just weight loss in a syringe” understates a large, real histologic effect that arrives bundled with the metabolic and cardiovascular benefits GLP-1s bring. The genuine unknown — the hard clinical outcomes — is what the next few years will settle.

Frequently asked questions

Is Wegovy approved for fatty liver? Yes. In August 2025 the FDA granted accelerated approval to semaglutide 2.4 mg (Wegovy) for noncirrhotic MASH — the inflammatory, scarring form of fatty liver — with moderate-to-advanced (F2–F3) fibrosis, alongside diet and physical activity. It is not approved for simple fatty liver (MASLD without significant inflammation and scarring) or for cirrhosis.

Does the GLP-1 reverse liver scarring? In the ESSENCE trial, liver scarring improved by at least one stage without worsening the steatohepatitis in about 37% of people on semaglutide versus 22% on placebo at 72 weeks. That is meaningful improvement on biopsy, but it is not the same as proof that the drug prevents progression to cirrhosis or liver failure — that longer-term outcome is still being studied.

Can tirzepatide (Mounjaro/Zepbound) treat MASH? A phase-2 trial (SYNERGY-NASH) showed promising liver results, but tirzepatide is not FDA-approved for MASH as of mid-2026, and phase-2 evidence is not the same as an approval. It remains investigational for the liver.